We developed an assay to detect antibodies spontaneously secreted in vitro by peripheral blood mononuclear cells (PBMC) against Brucella spp. High levels of anti-Brucella immunoglobulin G (IgG) and/or IgM and/or IgA antibodies were detected in the cell supernatant solution of PBMC cultures for 12 patients suffering from acute or focalized brucellosis and for 5 patients recently vaccinated against brucellosis. This spontaneous in vitro antibody production disappeared 5 to 20 months after onset of clinical signs and 20 to 27 days after vaccination. The transient character of this anti-Brucella antibody production by PBMC is consistent with a temporary in vivo stimulation of the immune system by Brucella antigens. Detection of this secretion could improve the diagnosis of evolutive brucellosis.
Brucella spp., facultative intracellular gram-negative bacteria, are responsible for a zoonosis distributed worldwide. The pathophysiology of human brucellosis remains poorly documented (8) . In acute brucellosis, the patient has a bacteremia resulting from multiplication of Brucellae in lymphoid organs. This acute stage is sometimes asymptomatic. In the course of the acute infection, Brucellae can specifically colonize organs such as the liver, heart, bones, or joints, etc., leading in some cases to focalized brucellosis or to so-called chronic brucellosis (15) .
The acute stage of the disease is usually diagnosed by isolation of Brucellae from blood and by serological tests. In focalized or chronic brucellosis, difficulties in diagnosis may result from the inability to isolate Brucellae from blood and from low anti-Brucella antibody titers in serum (14) . We evaluated an assay based on the detection of in vitro production of antibodies to Brucella antigens by peripheral blood mononuclear cells (PBMC), as described in other models of infection (1, 4, 7, 11) .
The population studied consisted of 25 adult subjects divided into three groups on the basis of clinical criteria. The first group consisted of six patients suffering from acutestage brucellosis. The second group included six patients with focalized brucellosis (patient 7, appendicitis; patients 8 and 11, sacroiliitis; patient 9, spondylitis; and patients 10 and 12, chronic abscesses). The third group consisted of 13 individuals who had presented the acute stage of brucellosis between 9 months (patient 13) and 28 years (patient 24) before the study, with cutaneous reactions >2.5 mm in diameter after intradermal injection of 0.1 ml of phenolsoluble antigen from Brucella abortus (2). Among these patients, patients 13 and 14 had so-called chronic brucellosis. Five healthy male volunteers (patients 26 to 30) who were 27 to 45 years old and were each vaccinated with an injection of 0.5 mg of a phenol-insoluble fraction of Brucella organisms (6) were also studied. Three subjects (patients 26, * Corresponding author. 27, and 30) were initially seronegative for brucellae, but two other subjects (patients 28 and 29) were seropositive; subject 28 had never shown symptoms of brucellosis, whereas subject 29 had been vaccinated nine years prior to experimentation. Negative controls (group IV) consisted of 10 healthy volunteers (6 males and 4 females, aged 27 to 56 years) without a history of brucellosis and seronegative for anti-Brucella antibodies.
PBMC were prepared and cultured as previously described (12) . Anti-Brucella antibodies were detected by enzyme immunoassay as previously reported (10 Brucella-specific antibodies were also detected in supernatant solutions of PBMC recovered from the five immunized subjects at day 11 after vaccination (Fig. 1A) . IVAP decreased dramatically on day 20 and disappeared on day 27, whereas anti-Brucella antibody levels in serum did not decrease (Fig. 1B) . Anti-Brucella IgG and IgA antibodies were found in supernatants of specimens from all these subjects, but the IgM isotype was detected only in the supernatant of PBMC from subject 26.
To determine whether antibodies detected in cell supernatant solutions resulted from active secretion of antibodies or from plasma antibodies' being passively adsorbed onto PBMC membranes and released during the cell culture, we performed two sets of experiments. (i) PBMC from five patients seropositive for anti-Brucella antibody (patients 6, 9, 11, 19, and 22) were preincubated for 1 h at 37°C in culture medium and then washed several times. As shown in Table  2 , the ELISA indices of these cell supernatant solutions recovered after this preincubation of PBMC were positive and ranged from 1.80 (patient 19) to >4.96 (patient 11). In contrast, PBMC supematant solutions recovered after 1 h of culture did not contain Brucella-specific antibody (ELISA index, <1). This indicates that antibodies adsorbed onto PBMC were released during the preliminary incubation and were eliminated by washing (patients 19 and 22), whereas antibodies detected after 168 h of culture corresponded to de novo antibody production (patients 6, 9, and 11). (ii) A total of 5 x 106 PBMC from two Brucella-infected patients with acute-stage brucellosis (patients 6 and 9) were cultured with 50 ,ug of cycloheximide (an inhibitor of protein synthesis) for 7 days. This treatment led to a 75% decrease in ELISA indices for both patients.
Antibody specificity was assessed as previously described (12) . Briefly, 1 ml of PBMC supernatant solutions for patients 3; 9, 11, 21, and 23 was treated with 108 formalin-killed B. suis cells or 108 heat-killed Eschenchia coli cells, centrifuged for 1 h at 10,000 x g, and assayed for anti-Brucella antibodies. Incubation of cell supernatant solutions with Brucella antigens led to decreases in antibody levels of 54% for patient 21 and 86.4% for patient 9, whereas E. coli antigen-adsorbed PBMC supernatant solutions showed a decrease of only 5.5% (P < 0.05).
To assess the anti-Brucella antibody production during the course of brucellosis, PBMC secretion was investigated at various intervals after the onset of clinical signs in five patients of group I (patients 2 through 6) and three patients of group II (patients 9, 11, and 12). This follow-up showed that antibody secretion decreased and disappeared at between 5 months (patient 12) and 20 months (patient 11) (data not shown).
PBMC from patients suffering from acute and focalized brucellosis secreted high levels of anti-Brucella antibodies, whereas in patients with a long history of brucellosis, Brucella-specific IVAP disappeared or dramatically decreased. This observation indicates that anti-Brucella antibody secretion by PBMC was transient during the course of the disease. This transient character is also observed after vaccination with Brucella antigens.
Transient IVAP in several models of experimental immunization, such as tetanus toxoid (9) and poliovirus (3), and during the course of acute gastrointestinal infections (4) has been reported. Antibodies produced in PBMC cultures were detectable when PBMC were recovered from 5 to 30 days after immunization or onset of clinical symptoms. In contrast, in chronic infections such as human immunodeficiency virus infection, IVAP has been detected at all stages of the disease (1, 11) . The transient or persistent character of IVAP is considered a reflection of temporary (9) or continuous (5, 13) in vivo antigenic stimulation of the immune system.
Results for our Brucella model suggest that in acute and focalized brucellosis, the immune system of the host is stimulated by Brucella antigens for several months after the onset of illness. However, weak Brucella-specific IVAP was detected in six patients with a long history of focalized 
